Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1020 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-03

Study Completion Date

2022-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

NCT06500741

Prostate Cancer

COMPLETED

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00527124

Adenocarcinoma of the Prostate Stage IV Prostate Cancer

TERMINATED PHASE2

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

NCT01260688

Hormone Refractory Prostate Cancer Recurrent Prostate Cancer

COMPLETED PHASE2

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924

Prostate Cancer (Adenocarcinoma)

RECRUITING PHASE3

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

NCT00055731

Prostate Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Metastatic Hormone-sensitive Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For interviews (attribute prioritization and pretest interviews)

* Diagnosis of mHSPC with or without previous experience with ADT
* Able to read and understand the survey language
* Able to provide informed consent For online survey
* Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
* Able to read and understand the survey language
* Able to provide informed consent